3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms by Site
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms
1
Lung Diseases
1
Head and Neck Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Bronchial Neoplasms
1
Interventions
Gemcitabine
57
Paclitaxel
50
Cyclophosphamide
45
pembrolizumab
44
Carboplatin
41
Bevacizumab
38
Cisplatin
33
Docetaxel
31
Fluorouracil
30
Nivolumab
29
Capecitabine
29
Pemetrexed
24
Irinotecan
24
Oxaliplatin
23
Dexamethasone
23
Ipilimumab
22
Leucovorin
21
Radiotherapy
20
Sorafenib
19
Doxorubicin
19
Everolimus
18
Cetuximab
18
fludarabine
17
Albumin-Bound Paclitaxel
17
trametinib
15
Sunitinib
15
Rituximab
15
Erlotinib Hydrochloride
15
130-nm albumin-bound paclitaxel
15
Prednisone
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms
×
patritumab
×
Clear all
NCT02134015
2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3
Terminated
145 enrolled
20 charts